LENZ Therapeutics, Inc.(LENZ)
Search documents
LENZ Therapeutics, Inc.(LENZ) - 2023 Q4 - Annual Report
2024-02-27 21:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC. (Exact name of Registrant as specified in its charter) Delaware 2836 84-4867570 (State or other jurisdiction ...
LENZ Therapeutics, Inc.(LENZ) - 2023 Q3 - Quarterly Report
2023-11-13 21:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ | --- | --- | |-----------------------------------------------------------------------------------------|----------------------------------- ...
LENZ Therapeutics, Inc.(LENZ) - 2023 Q2 - Quarterly Report
2023-08-14 21:04
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------|------ ...
LENZ Therapeutics, Inc.(LENZ) - 2023 Q1 - Quarterly Report
2023-05-11 20:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------|----- ...
LENZ Therapeutics, Inc.(LENZ) - 2022 Q4 - Annual Report
2023-03-20 20:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC. (Exact name of Registrant as specified in its charter) Delaware 2836 84-4867570 (State or other jurisdiction ...
LENZ Therapeutics, Inc.(LENZ) - 2022 Q3 - Quarterly Report
2022-11-09 21:14
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 001-40532 GRAPHITE BIO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 84-4867570 ( State or o ...
LENZ Therapeutics, Inc.(LENZ) - 2022 Q2 - Quarterly Report
2022-08-11 20:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in its Charter) Delaware 84-4867570 ( State or other jurisdiction of incorporation or organization) 201 Haskins Way, Suite 210 South San Francisco, CA 94080 (I.R.S. Employer Identification No.) (Address of principal executive offices) (Zip Code) For the quarterly period ended June 30, 2022 O ...
LENZ Therapeutics, Inc.(LENZ) - 2022 Q1 - Quarterly Report
2022-05-12 20:12
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 001-40532 GRAPHITE BIO, INC. (Exact Name of Registrant as Specified in its Charter) (I.R.S. Employer Identification No.) ...
LENZ Therapeutics, Inc.(LENZ) - 2021 Q4 - Annual Report
2022-03-21 12:31
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or orga ...
LENZ Therapeutics, Inc.(LENZ) - 2021 Q3 - Quarterly Report
2021-11-10 21:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 001-40532 GRAPHITE BIO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 84-4867570 ( State or o ...